Mammary analog secretory carcinoma of salivary gland is a recently described entity with unique morphologic, clinical, and genetic characteristics, including the characteristic t(12;15)(p13;q25) with ETV6-NTRK3 translocation found in secretory carcinomas of the breast. Before their initial description, these salivary gland tumors were generally diagnosed as acinic cell carcinoma or adenocarcinoma. For the purpose of this study, all cases of salivary gland acinic cell carcinoma, cribriform cystadenocarcinoma, and adenocarcinoma, not otherwise specified (NOS), diagnosed over a 10-year period were retrieved from our surgical pathology files. There were a total of 11 cases diagnosed as acinic cell carcinoma, 10 cases of adenocarcinoma, NOS, and 6 cases of cribriform cystadenocarcinoma. All slides were reviewed by two pathologists (AP, CGF) and tumors that show morphologic features of mammary analog secretory carcinoma according to the recent literature were selected. This process narrowed down the initial number to six cases originally diagnosed as acinic cell carcinoma, three cases originally diagnosed as adenocarcinoma, NOS, and one case originally diagnosed as cribriform cystadenocarcinoma. The 10 cases were subjected to immunohistochemistry for S-100, mammaglobin, and ANO1, as well as fluorescence in situ hybridization analysis for t(12;15)(p13;q25) with ETV6-NTRK3 fusion rearrangement. The ETV6-NTRK3 gene rearrangement was detected in three tumors. These three tumors, initially diagnosed as acinic cell carcinomas, stained positive for S-100 and mammaglobin, and negative for ANO1 by immunohistochemistry. Two of the three patients were male (2/3). In summary, mammary analog secretory carcinoma is a newly described diagnostic entity that should be in the differential diagnosis of salivary gland tumors that morphologically mimic other neoplasms, mainly acinic cell carcinomas. They differ from conventional acinic cell tumors immunohistochemically and molecularly. Positivity for mammaglobin and S-100, and negativity for ANO1 are useful screening tools before confirmatory molecular studies.
Mammary analog secretory carcinoma of the salivary gland is a recently described tumor with unique characteristics. The first description of mammary analog secretory carcinoma reported by Skalova et al 1 in 2010 included 16 cases of this new entity that shares morphologic and genetic characteristics with its mammary counterpart, including the ETV6-NTRK3 fusion product previously described in secretory carcinomas of the breast. The authors selected their cases among salivary gland neoplasms that morphologically resemble secretory carcinomas of the breast; ie, well-circumscribed nodules of neoplastic epithelial cells arranged in solid, microcystic, and tubular growth patterns associated with intraluminal secretions. Cytologically, the cells are bland, have vesicular nuclei and abundant pale-pink granular or vacuolated cytoplasm. 1, 2 Following the initial publication describing mammary analog secretory carcinoma, other investigators began to look back at their own institutional cases in order to reanalyze some of their salivary gland tumors. Acinic cell carcinomas, adenocarcinomas, not otherwise specified (NOS), polymorphous lowgrade adenocarcinomas, mucoepidermoid carcinomas, and cystadenocarcinomas are examples of cases re-evaluated in a small number of recently published studies, describing additional cases of mammary analog secretory carcinoma. Most cases of mammary analog secretory carcinoma had been initially classified as acinic cell carcinomas. [3] [4] [5] [6] [7] Immunohistochemistry studies may be useful in the differential diagnosis between mammary analog secretary carcinoma and its mimics. The former are reactive for S-100 protein and mammaglobin in the vast majority of cases, 1, [3] [4] [5] [6] 8 however, these two markers, S-100 in particular, are likewise found to be occasionally positive in other adenocarcinomas of salivary gland origin. Acinic cell carcinomas tend to be negative for mammaglobin, but can rarely demonstrate immunoreactivity for S-100. ANO1 (also known as DOG1), initially described in gastrointestinal stromal tumors, is a marker of salivary acinar and intercalated duct differentiation. A recent study by Chenevert et al, described the positive immunohistochemical expression of the ANO1 protein in all of their cases of acinic cell carcinomas, whereas the mammary analog secretory carcinomas were largely negative for this marker. 9 Molecularly, mammary analog secretory carcinomas, like their breast counterpart, harbor a balanced translocation t(12;15)(p13;q25), which creates an ETV6-NTRK3 fusion gene. 1 This same genetic aberration is also seen in cellular mesoblastic nephroma, 10 congenital fibrosarcoma, 11 and in some hematologic malignancies, 12,13 but has not been described in other neoplasms of the salivary gland.
The aim of this study is to reanalyze our own database of salivary gland cases for the presence of mammary analog secretory carcinoma using the recently described morphologic criteria, together with immunohistochemistry for mammaglobin, S-100, and DOG1 and fluorescent in situ hybridization (FISH) analyses for ETV6-NTRK3 translocation product.
Materials and methods
All cases of acinic cell carcinoma, adenocarcinoma NOS, and cribriform cystadenocarcinoma of salivary gland origin, from three institutions (Jackson Memorial Hospital, Sylvester Comprehensive Cancer Center, and University of Miami Hospital) over a 10-year period, were retrieved. A total of 27 cases were identified, including 11 cases of acinic cell carcinoma, 10 cases of adenocarcinoma NOS, and 6 cases of cribriform cystadenocarcinoma.
Hematoxylin and eosin stained slides were reviewed, and tumors that morphologically resembled mammary analog secretory carcinoma according to the recent literature were selected. Those features included epithelial cells with abundant vacuolated cytoplasm, minimal nuclear pleomorphism, papillary, and microcystic architecture with cellular hobnailing and eosinophilic secretions (Figure 1 ).
This process narrowed down the initial number to 10 cases (6 acinic cell carcinomas, 3 adenocarcinomas, NOS, and 1 cribriform cystadenocarcinoma) on which S-100, mammaglobin and ANO1 (DOG1) immunostains were performed (Table 1) . Immunohistochemistry was performed using Dako antibodies in 5-mm paraffin-embedded tissues using appropriate tissue-positive controls. All immunohistochemical staining was performed on automatic stainers using antibody dilutions previously determined by pathologists during antibody validation, after appropriate antigen retrieval. Antigen retrieval was performed in a pre-treatment station using both low pH (pH 6, citrate buffer) and high pH (pH 9, EDTA buffer) environments. Staining detection was carried out using a modified biotin-streptavidinhorseradish peroxidase method ( Figure 2 ).
FISH analysis for the characteristic t(12;15) (p13;q25) with ETV6-NTRK3 fusion was performed using slides prepared from formalin-fixed paraffinembedded tissues with 3-mm-thick sections. A dual color ETV6-NTRK3 break-apart FISH probe (Abbot Molecular, Des Plaines, Illinois, USA) was used to detect translocation and copy number changes of the ETV6-NTRK3 gene. FISH was performed using a protocol recommended by the manufacturer of the DNA probe. The major steps included slide deparaffinization, codenaturation of probe DNA and tissue materials on slides, hybridization, post hybridization washes, and counterstaining with DAPI. Hybridization signals were analyzed with a fluorescence microscope equipped with a Cytovision system for image capturing and storage (Applied Imaging Corp, USA). For each case, 200 cells were analyzed with result described using the standard cytogenetics nomenclature (ISCN, 2009). 14 
Results
FISH studies confirmed ETV6-NTRK3 rearrangement in 3 of the 10 cases. These three tumors had been initially diagnosed as acinic cell carcinoma. Immunohistochemistry studies demonstrated that each was positive for S-100 and mammaglobin and negative for ANO1 ( Table 2) .
The ages for the three patients with tumors harboring the ETV6-NTRK3 translocation ranged from 29 to 61 years (average 47.6, median 53 years). Two of the patients were male. Grossly, the tumors were generally described as circumscribed, gray-tan cystic masses, and ranged from 1.8 cm to 3.0 cm in greatest dimension. Histologically, all cases demonstrated a mixture of micropapillary, microcystic, and solid patterns of growth with an overall lobulated architecture. The microcystic spaces contained characteristic eosinophilic bubbly secretions, whereas the micropapillary growth pattern consisted of tumor cells surrounding a fibrovascular core in a 'hobnail' pattern. The tumor cells had minimal nuclear pleomorphism with abundant eosinophilic or vacuolated cytoplasm. No necrosis, perineural, or lymphovascular invasion was identified in any of the cases in our series. Lymph node Mammary analog secretory carcinoma metastasis was present in one confirmed case on which node dissection was performed. No distant metastases were identified at the time of presentation in any of patients ( Figure 3) . With respect to the other cases in our study subjected to FISH analysis and immunohistochemistry, one case demonstrated amplification of the ETV6 gene, and one case had deletion of ETV6. Both of these cases belonged to male patients. The remaining five cases had no cytogenetic abnormalities detected. By immunohistochemistry, the three cytogenetically confirmed cases were positive for S-100 and mammglobin and negative for DOG1. Interestingly, there was one other case with the same Figure 2 Immunohistochemical profile of the MASC cases identified in this study. All tumors were immunoreactive for S-100, which in this example had strong and diffuse staining (a). Mammaglobin (MMG) is positive in MASC, as this entity represents the salivary gland counterpart of the breast carcinoma (b). DOG1, a marker for acinic cell differentiation, is negative in MASC. Notice the remaining nonneoplastic acini with the typical intercalated duct staining in the upper left corner (c). All figures: immunohistochemical stains; x200 original magnification. 
Discussion
The recent identification of mammary analog secretory carcinoma as a primary salivary gland tumor with a characteristic molecular alteration, but with morphologic features that overlap primarily with those of acinic cell carcinoma has prompted several groups to review their archival cases. Acinic cell carcinomas have a broad spectrum of histologic patterns, including solid, microcystic, papillarycystic, and follicular. Thus, salivary gland tumors with these architectural features, have been historically classified as acinic cell carcinomas, and to a lesser extent, as adenocarcinomas NOS. 3, 4, 7 Other entities like cystadenocarcinoma and mucoepidermoid carcinoma have also been used as potential diagnoses for what we now understand may represent mammary analog secretory carcinoma. 3 In determining the diagnostic categories for the retrospective analysis of our archival cases, acinic cell tumors were selected as most of the newly diagnosed mammary analog secretory carcinomas have been shown to be initially classified as such. Cribriform cystadenocarcinomas have also been cited as possible diagnoses for mammary analog secretory carcinomas. We also decided to include cases diagnosed as adenocarcinoma, NOS, as 'unclassifiable' salivary gland adenocarcinomas may be inadvertently placed into this category as a diagnosis of exclusion. We chose not to review other tumors types (polymorphous low-grade adenocarcinoma, mucoepidermoid carcinoma, among others) as these have specific histomorphologic characteristics, which we believe are separate and distinct from those in the classic description of mammary analog secretory carcinoma.
In the review of our cases, we found that the overlap between mammary analog secretory carcinoma and acinic cell carcinoma, in particular, may be quite striking. As an example, one of our cases diagnosed as acinic cell carcinoma was morphologically and immunophenotypically indistinguishable from mammary analog secretory carcinoma but failed to show the characteristic ETV6-NTRK3 gene rearrangement by FISH, underscoring the importance of this ancillary technique in this differential (Figure 4) .
Reclassifying tumors is becoming a regular exercise for the modern pathologist. Supported by the increasing sophistication and feasibility of molecular techniques, this practice is becoming more and more common on a routine basis, and this may or may not have significant clinical implications for the patient. When, for instance, two neoplasms that have distinct genetic profiles, but similar therapeutic options and outcomes, are separated, no major impact is produced clinically. However, if tumors are biologically distinct enough to the point that the treatment will differ, we as pathologists have a major role in patient care.
This phenomenon still seems unclear when analyzing the behavior of mammary analog secretory carcinoma because of the paucity of cases reported. A male predilection is undoubtedly noted, 1,3-5 and differs from acinic cell carcinoma, which has a slight female predominance. Parotid is the salivary gland most commonly involved, 1,3,5 although these tumors may occur in other major and minor salivary glands. A recent study has suggested that 'acinic cell carcinomas' that occur outside of the parotid are actually mammary analog secretory carcinomas. 15 A higher incidence of nodal metastasis and poorer disease-free survival seem to occur when compared with acinic cell carcinoma. 3,4 Figure 3 Adenocarcinoma, NOS. Although this case had areas that resembled MASC-like abundant eosinophilic cytoplasm, nuclear pleomorphism and histological grade were higher than typically seen on this recently recognized entity. This case was also strongly positive for S-100 (b). a: H&E, x400 original magnification, b: x200 original magnification.
Our data revealed a higher predominance of these tumors in men, which correlates with the current literature. Immunohistochemistry for S-100 seems to be a very useful technique for distinguishing mammary analog secretory carcinoma, typically positive for this marker, from acinic cell carcinoma, reported to be positive in only 10% of cases. 16, 17 The S-100 staining pattern for mammary analog secretory carcinoma can range from partial to diffuse and from weak to intense. However, it is important to remember that this marker has to be used in conjunction with morphology, as many 18 Similar to its mammary counterpart, mammary analog secretory carcinomas are positive for mammaglobin. 1, 6, 19 Although reportedly negative in most cases of acinic cell carcinoma, 1,15 this marker has not been widely tested among other salivary gland tumors. Table 3 contains a review of studies about the expression of S-100 and mammaglobin in mammary analog secretory carcinomas.
ANO1, also known as DOG1, was recently shown to be an indicator of salivary acinar cell and intercalated duct differentiation. 9 It tends to be positive in acinic cell carcinoma, with a characteristic apical-luminal membranous and intercalated duct staining, and negative in mammary analog secretory carcinoma. Therefore, this stain may be used as a negative marker in an immunohistochemical panel for distinguishing cases with morphologic overlap between mammary analog secretory carcinoma and acinic cell carcinoma. All the cases initially classified as acinic cell tumors in our series demonstrated negative immunoreactivity for this marker, and were re-classified as mammary analog secretory carcinomas after FISH studies showed a positive ETV6 translocation.
Of note, an unusual finding in our study was the presence of ETV6 amplification in tumor cells seen in one case, and deletion of this gene in the majority of cells in another. Both tumors were present in the parotid gland of male patients. The significance of these genetic alterations remain unclear, however, they may indicate that alternative pathways involving the ETV6-NTRK3 gene could be related to the pathogenesis of this tumor, assuming that those cases represent mammary analog secretory carcinoma.
Conclusion
Mammary analog secretory carcinoma is a new diagnostic entity that should be in the differential diagnosis of salivary gland tumors that predominantly mimic acinic cell carcinoma. Although morphologically similar, they differ from conventional acinic cell carcinoma immunohistochemically and molecularly. They predominantly affect male patients. Positivity for mammaglobin and S-100 and negativity for ANO1 are useful screening tools before further confirmatory cytogentic studies demonstrating the ETV6-NTRK3 fusion product.
